Date |
Symbol |
Description |
Type |
Disease |
Designation |
Success Rating |
Q4 2017
|
VBLT |
|
Phase 3 Results |
Oncology |
Fast Track, Orphan Drug |
|
H2 2017
|
AIMT |
|
Phase 3 Results |
Other |
Breakthrough Therapy |
|
H2 2017
|
ARDX |
|
Phase 3 Results |
Other |
None |
|
H2 2017
|
ARDX |
|
Phase 3 Results |
Other |
None |
|
H2 2017
|
AXSM |
|
Phase 3 Results |
Other |
Fast Track |
|
H2 2017
|
EARS |
|
Phase 3 Results |
Other |
Orphan Drug |
|
Q4 2017
|
ESPR |
|
Phase 3 Results |
Other |
None |
|
H2 2017
|
EXEL |
|
Phase 3 Results |
Oncology |
None |
|
H2 2017
|
GNVC |
|
Phase 1/2 Results |
Other |
None |
|
H2 2017
|
GWPH |
|
Phase 3 Results |
Oncology |
Orphan Drug |
|